E-LIB Suche - Ergebnisse für: Kapner, Kevin S. - Sprache EN

Search for persons X

Sorted by: Year

Sorted by: Relevance

1

Adeno-to-squamous transition drives resistance to KRAS inhi..:

Tong, Xinyuan ; Patel, Ayushi S. ; Kim, Eejung...
Cancer Cell. 42 (2024) 3 - p. 413-428.e7 , 2024

Link: https://doi.org/10.1016/..

2

Sotorasib Is a Pan-RASG12C Inhibitor Capable of Driving Cli..:

Rubinson, Douglas A. ; Tanaka, Noritaka ; Fece de la Cruz, Ferran...
Cancer Discovery. 14 (2024) 5 - p. 727-736 , 2024

Link: https://doi.org/10.1158/..

3

Mechanisms of resistance to oncogenic KRAS inhibition in pa..:

Dilly, Julien ; Hoffman, Megan T. ; Abbassi, Laleh...
Cancer Discovery. , 2024

Link: https://doi.org/10.1158/..

4

Supplementary Figures S1-S2 from A Phase I Expansion Cohort..:

Brandon M. Huffman ; Hanrong Feng ; Kalindi Parmar...
doi:10.1158/1078-0432.24825277.v1. , 2023

Link: https://doi.org/10.1158/..

5

Supplementary Figure S4 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558754.v1. , 2023

Link: https://doi.org/10.1158/..

6

Supplementary Table S12 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558724.v1. , 2023

Link: https://doi.org/10.1158/..

7

Supplementary Table S18 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558703.v1. , 2023

Link: https://doi.org/10.1158/..

8

Supplementary Figure S8 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558739.v1. , 2023

Link: https://doi.org/10.1158/..

9

Supplementary Table S4 from Oncogenic Drivers and Therapeut..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558694.v1. , 2023

Link: https://doi.org/10.1158/..

10

Supplementary Figure S6 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558748.v1. , 2023

Link: https://doi.org/10.1158/..

11

Supplementary Figure S10 from Oncogenic Drivers and Therape..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558766.v1. , 2023

Link: https://doi.org/10.1158/..

12

Supplementary Table S8 from Oncogenic Drivers and Therapeut..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558682.v1. , 2023

Link: https://doi.org/10.1158/..

13

Supplementary Figure S9 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558736.v1. , 2023

Link: https://doi.org/10.1158/..

14

Supplementary Figure S5 from Oncogenic Drivers and Therapeu..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558751.v1. , 2023

Link: https://doi.org/10.1158/..

15

Supplementary Table S5 from Oncogenic Drivers and Therapeut..:

Harshabad Singh ; Rachel B. Keller ; Kevin S. Kapner...
doi:10.1158/1078-0432.24558691.v1. , 2023

Link: https://doi.org/10.1158/..

1-15